Expert Opinion on Pharmacotherapy最新文献

Pharmacotherapeutic options for the treatment of hypertension in pregnancy. 治疗妊娠高血压的药物治疗方案。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-09-09 DOI: 10.1080/14656566.2024.2398602

Frances Conti-Ramsden, Antonio de Marvao, Lucy C Chappell

{"title":"Pharmacotherapeutic options for the treatment of hypertension in pregnancy.","authors":"Frances Conti-Ramsden, Antonio de Marvao, Lucy C Chappell","doi":"10.1080/14656566.2024.2398602","DOIUrl":"10.1080/14656566.2024.2398602","url":null,"abstract":"Introduction: Hypertensive disorders of pregnancy affect approximately one in 10 pregnancies and are associated with increased risk of adverse fetal, neonatal and maternal outcomes. There is strong evidence that effective treatment of hypertension (blood pressure ≥ 140/90 mmHg), and enhanced monitoring throughout pregnancy reduces these risks.Areas covered: This article provides a contemporaneous review of treatment of hypertension in pregnancy with antihypertensive agents. We completed a systematic search and review of all meta-analyses and systematic reviews of studies comparing antihypertensives for treatment of pregnancy hypertension in the last five years. We provide a clinically focused summary of when to treat hypertension in pregnancy and which antihypertensive agents can be offered. Special scenarios reviewed include treatment-resistant hypertension and pre-pregnancy antihypertensive optimization.Expert opinion: Several antihypertensives are considered safe and are known to be effective for treatment of hypertension in pregnancy. Given the current uncertainty as to which antihypertensive(s) are superior for treatment of hypertension in pregnancy, women should be counselled and offered a range of antihypertensive options in keeping with evidence on clinical effectiveness, local context and availability of antihypertensive(s), potential side effect profile, and women's preference. Further research is required to help guide clinical decision making, and move toward personalized treatment.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142119350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacological management of chronic lymphocytic leukemia: current and emerging therapies. 慢性淋巴细胞白血病的药物治疗：现有疗法和新兴疗法。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-09-08 DOI: 10.1080/14656566.2024.2398603

Ivan J Huang, Grace T Baek, Chloe Siu, Mazyar Shadman

{"title":"Pharmacological management of chronic lymphocytic leukemia: current and emerging therapies.","authors":"Ivan J Huang, Grace T Baek, Chloe Siu, Mazyar Shadman","doi":"10.1080/14656566.2024.2398603","DOIUrl":"10.1080/14656566.2024.2398603","url":null,"abstract":"Introduction: Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), characterized by its monoclonal lymphoproliferative nature, is an indolent but incurable malignancy. The treatment landscape of CLL/SLL has drastically transformed in the last decade since the introduction of targeted therapy and immune-effector T-cell therapy. The paradigm shift from chemoimmunotherapy to targeted and cellular therapies was largely driven by improved efficacy and safety. With the success of targeted therapies, novel agents and combinations are rapidly emerging on the horizon.Areas covered: In this review, we will summarize clinical evidence supporting current and emerging therapies with emphasis on investigational therapies and novel combinations of commercial agents. Clinical trials were identified via clinicaltrials.gov, and a PubMed literature search was last performed in June 2024.Expert opinion: With the availability of more effective and better-tolerated treatments for CLL/SLL, the role of early intervention should be further investigated due to its potential to alter disease course, delay progression, and improve overall survival rates. With many highly effective agents and combinations expected to become commercially available, attention to safety profiles and careful selection of patients for each treatment will be critical, with consideration of comorbidities, logistical issues, and financial burden of treatment.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Talazoparib for the treatment of prostate cancer. 用于治疗前列腺癌的 Talazoparib。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-08-29 DOI: 10.1080/14656566.2024.2397002

Arshit Narang, Chadi Hage Chehade, Zeynep Irem Ozay, Blake Nordblad, Umang Swami, Neeraj Agarwal

{"title":"Talazoparib for the treatment of prostate cancer.","authors":"Arshit Narang, Chadi Hage Chehade, Zeynep Irem Ozay, Blake Nordblad, Umang Swami, Neeraj Agarwal","doi":"10.1080/14656566.2024.2397002","DOIUrl":"https://doi.org/10.1080/14656566.2024.2397002","url":null,"abstract":"Introduction: Around 25% of patients with advanced prostate cancer harbor alterations in the homologous recombination/DNA damage repair (HRR) pathway. Inhibiting poly (ADP-ribose) polymerase (PARP) in these patients leads to synthetic lethality, making PARP inhibitors (PARPi), including talazoparib, a promising treatment for metastatic castration-resistant prostate cancer (mCRPC) and potentially for metastatic hormone-sensitive prostate cancer (mHSPC).Areas covered: This article examines the mechanism of action, chemical properties, pharmacokinetics, pharmacodynamics, and clinical safety and efficacy data of different PARPis, including talazoparib in prostate cancer. It reviews the TALAPRO-1 and TALAPRO-2 clinical trials and the ongoing TALAPRO-3 trial.Expert opinion: Despite recent therapeutic advancements, mCRPC remains a lethal disease. Androgen receptor pathway inhibitors (ARPIs) are approved for patients with mCRPC and mHSPC, yet most patients first receive these agents in the castration-resistant setting. Real-world data indicate that around half of patients with mCRPC do not receive subsequent lines of therapy, underscoring the efficacy of upfront combination therapies. The combinations of ARPI plus PARPi are indicated for patients with mCRPC harboring HRR mutations, though identifying these patients is challenging due to limited genomic testing. Further research and improved access to genomic testing are essential to optimize treatment strategies.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The evolving landscape of polycythemia vera therapies. 多发性红细胞增多症疗法不断发展。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-08-01 Epub Date: 2024-08-11 DOI: 10.1080/14656566.2024.2387681

Juana Martinez, Shivani Handa, Alexander Skorodinsky, Marina Kremyanskaya

{"title":"The evolving landscape of polycythemia vera therapies.","authors":"Juana Martinez, Shivani Handa, Alexander Skorodinsky, Marina Kremyanskaya","doi":"10.1080/14656566.2024.2387681","DOIUrl":"10.1080/14656566.2024.2387681","url":null,"abstract":"Introduction: The treatment landscape of polycythemia vera (PV) has seen major advancements within the last decade including approval of ruxolitinib in the second line setting after hydroxyurea, ropegylated interferon-α2b, and advanced clinical development of a novel class of agents called hepcidin mimetics.Areas covered: We provide a comprehensive review of the evidence discussing the risk stratification, treatment indications, role and limitations of phlebotomy only approach and pivotal trials covering nuances related to the use of interferon-α (IFN-α), ruxolitinib, hepcidin mimetics, and upcoming investigational agents including HDAC and LSD1 inhibitors.Expert opinion: The research paradigm in PV is slowly shifting from the sole focus on hematocrit control and moving toward disease modification. The discovery of hepcidin mimetics has come as a breakthrough in restoring iron homeostasis, achieving phlebotomy-independence and may lead to improved thrombosis-free survival with stricter hematocrit control. On the other hand, emerging data with IFN- α and ruxolitinib as well as combination of the two agents suggests the potential for achieving molecular remission in a subset of PV patients and long-term follow-up is awaited to validate the correlation of molecular responses with clinically relevant outcomes of progression-free and thrombosis-free survival.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141893284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of prescribing patterns of switching to and add-on lemborexant in patients treated with hypnotic medication: a nationwide claims database study in Japan. 对接受催眠药治疗的患者改用和加用利眠宁的处方模式进行评估：日本全国索赔数据库研究。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-08-01 Epub Date: 2024-08-21 DOI: 10.1080/14656566.2024.2392018

Sachiko Tanaka-Mizuno, Kenichi Fujimoto, Kazuo Mishima, Yukinori Sakata, Toshiki Fukasawa, Kayoko Mizuno, Satomi Yoshida, Mika Ishii, Takehiro Taninaga, Naoki Kubota, Margaret Moline, Koji Kawakami

{"title":"Evaluation of prescribing patterns of switching to and add-on lemborexant in patients treated with hypnotic medication: a nationwide claims database study in Japan.","authors":"Sachiko Tanaka-Mizuno, Kenichi Fujimoto, Kazuo Mishima, Yukinori Sakata, Toshiki Fukasawa, Kayoko Mizuno, Satomi Yoshida, Mika Ishii, Takehiro Taninaga, Naoki Kubota, Margaret Moline, Koji Kawakami","doi":"10.1080/14656566.2024.2392018","DOIUrl":"10.1080/14656566.2024.2392018","url":null,"abstract":"Background: When considering changing hypnotic pharmacotherapy, lemborexant has attracted attention as a candidate due to its effectiveness and safety profile. However, few studies have investigated switching patterns in clinical practice.Research design and methods: We conducted a retrospective cohort study using a nationwide claims database. Patients prescribed a single hypnotic who either subsequently switched to (switching cohort) or were additionally prescribed (add-on cohort) lemborexant between July 2020 and December 2021 were identified. Proportion of successful switching was defined as remaining on lemborexant alone or without any hypnotic at 6 months after lemborexant initiation.Results: The success proportion was 70.1% in the switching cohort (n = 4,861) and 38.6% in the add-on cohort (n = 9,423). In the add-on cohort, the success proportion was lower in patients with a hypnotic history of ≥180 days (31.4%) and in patients whose prescribed hypnotic was a benzodiazepine or non-benzodiazepine (31.5% and 37.6%, respectively).Conclusion: The proportion of successful switching was higher in patients who switched to lemborexant than in those who added lemborexant as a concomitant treatment. The lower success proportion in the add-on cohort might be related to clinically more severe insomnia, and/or a concomitant prescription of benzodiazepine or non-benzodiazepine, from which discontinuation may be challenging.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141916488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacotherapy for cervical cancer: current standard of care and new perspectives. 宫颈癌的药物治疗：现行治疗标准与新视角。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-08-01 Epub Date: 2024-08-27 DOI: 10.1080/14656566.2024.2395379

Peter W Ketch, Rennan S Zaharias, Charles A Leath

{"title":"Pharmacotherapy for cervical cancer: current standard of care and new perspectives.","authors":"Peter W Ketch, Rennan S Zaharias, Charles A Leath","doi":"10.1080/14656566.2024.2395379","DOIUrl":"10.1080/14656566.2024.2395379","url":null,"abstract":"Introduction: Cervical cancer, while highly preventable, remains an international public health challenge especially in under resourced regions. Although early-stage cervix confined cancers are often amenable to surgical resection, larger tumors deemed locally advanced cervical cancer (LACC) necessitate systemic therapy as part of chemoradiation therapy. Moreover, systemic therapy is the standard therapeutic approach for those presenting with primary metastasis or recurrence.Areas covered: While several agents have been approved to treat recurrent cervical cancer including checkpoint inhibitors as well as both biomarker agnostic and specific antibody drug conjugates, the development of agents added to chemoradiation has been less fruitful. Until recently, the addition of novel therapies to chemoradiation has been negative in terms of improving outcomes; however, results of a recent Phase III clinical trial (NCT04221945) in LACC demonstrated that the addition of pembrolizumab to standard of care chemoradiation was associated with an improvement in progression-free survival and resulted in an FDA approval for this therapy. This observation led to the first change in treating LACC since the early 2000s.Expert opinion: Improvements in systemic therapy both alone and in combination with chemoradiation for cervical cancer have been realized. Ongoing research is needed for therapeutic options following immunotherapy.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142008537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy. 对接受化疗免疫疗法的广泛期小细胞肺癌患者进行 G-CSF 预防治疗的有效性和安全性。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-08-01 Epub Date: 2024-08-11 DOI: 10.1080/14656566.2024.2391007

Yusuf Ilhan, Gokhan Ucar, Mehmet Nuri Baser, Halil Goksel Guzel, Safa Can Efil, Bilgin Demir, Duygu Ercan Uzundal, Tuba Karacelik, Nadiye Sever, Onur Yazdan Balcik, Hayati Arvas, Ibrahim Karadag, Ahmet Kadioglu, Ömer Burak Ekinci, Cengiz Karacin, Zuhat Urakci, Osman Kostek, Melek Karakurt Eryilmaz, Ozan Yazici, Mehmet Ali Nahit Sendur, Banu Ozturk, Dogan Uncu, Yakup Ergun

{"title":"Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy.","authors":"Yusuf Ilhan, Gokhan Ucar, Mehmet Nuri Baser, Halil Goksel Guzel, Safa Can Efil, Bilgin Demir, Duygu Ercan Uzundal, Tuba Karacelik, Nadiye Sever, Onur Yazdan Balcik, Hayati Arvas, Ibrahim Karadag, Ahmet Kadioglu, Ömer Burak Ekinci, Cengiz Karacin, Zuhat Urakci, Osman Kostek, Melek Karakurt Eryilmaz, Ozan Yazici, Mehmet Ali Nahit Sendur, Banu Ozturk, Dogan Uncu, Yakup Ergun","doi":"10.1080/14656566.2024.2391007","DOIUrl":"10.1080/14656566.2024.2391007","url":null,"abstract":"Objectives: We aimed to evaluate the efficacy and safety of granulocyte-colony stimulating factor (G-CSF) prophylaxis during chemoimmunotherapy with carboplatin plus etoposide and atezolizumab in extensive-stage small cell lung cancer (ES-SCLC).Methods: This retrospective, multicenter study enrolled ES-SCLC patients receiving carboplatin plus etoposide and atezolizumab, categorized into G-CSF and non-G-CSF groups. Demographic and disease-related data were collected. Response rates, progression-free survival (PFS), overall survival (OS), and toxicity were analyzed.Results: Of 119 patients (median age: 63 years), the overall response rate (ORR) and disease control rate (DCR) were 72.3% and 81.5%, respectively. In the G-CSF group, the ORR was 76.4% compared to 60.0% in the non-G-CSF group (p = 0.33), and the DCR was 85.4% versus 70.0%, respectively (p = 0.46). Median PFS was 8.3 months (95% CI, 6.8-9.8) in the G-CSF group and 6.8 months (95% CI, 6.2-7.5) in the non-G-CSF group (p = 0.24). Median OS was 13.8 months (95% CI, 9.6-18.1) for the G-CSF group and 10.6 months (95% CI, 7.9-13.3) for the non-G-CSF group (p = 0.47). Grade 3 ≥ adverse events were similar between groups (49.4% vs. 33.3%, respectively, p = 0.12).Conclusion: G-CSF prophylaxis can be safely used in ES-SCLC patients undergoing carboplatin plus etoposide and atezolizumab regimen without significantly altering efficacy or increasing toxicity.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer. 使用酪氨酸激酶抑制剂治疗甲状腺癌的最新进展。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-08-01 Epub Date: 2024-08-28 DOI: 10.1080/14656566.2024.2393281

Silvia Martina Ferrari, Armando Patrizio, Giulio Stoppini, Giusy Elia, Francesca Ragusa, Eugenia Balestri, Chiara Botrini, Licia Rugani, Emilio Barozzi, Valeria Mazzi, Concettina La Motta, Alessandro Antonelli, Poupak Fallahi

{"title":"Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer.","authors":"Silvia Martina Ferrari, Armando Patrizio, Giulio Stoppini, Giusy Elia, Francesca Ragusa, Eugenia Balestri, Chiara Botrini, Licia Rugani, Emilio Barozzi, Valeria Mazzi, Concettina La Motta, Alessandro Antonelli, Poupak Fallahi","doi":"10.1080/14656566.2024.2393281","DOIUrl":"10.1080/14656566.2024.2393281","url":null,"abstract":"Introduction: Oncogenic tyrosine kinases (TK) are enzymes that play a key role in cell growth and proliferation and their mutations can lead to uncontrolled cell growth and development of aggressive cancer. This knowledge has led to the development of new classes of drugs, Tyrosine kinase inhibitors (TKI). They target oncogenic kinases who are associated with advanced radioactive iodine (RAI) refractory TC, which is not able to uptake RAI anymore and/or still grows between consecutive treatments with Iodine 131 (I131).Areas covered: Since Lenvatinib and Sorafenib approval, several other molecular inhibitors have been studied and then introduced for the treatment of aggressive and refractory thyroid cancer (TC), and, although the development of adverse effects or tumor resistance mechanisms, more and more compounds are still under investigation. The literature search was executed in PubMed and ClinicalTrials.gov to identify relevant articles and clinical trials published until December 2023.Expert opinion: In the context of clinical trials, driven by the presence of specific molecular mutations or even in the absence of both conditions, systemic therapy TKIs are valuable weapons to be used in patients affected by aggressive forms of TC, waiting for further expansion of the treatment landscape with more efficacious and safer drugs.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142003987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review. 丙型肝炎病毒感染的前沿药物疗法：全面回顾。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-08-01 Epub Date: 2024-08-26 DOI: 10.1080/14656566.2024.2396024

Chen-Hua Liu, Yu-Ping Chang, Jia-Horng Kao

{"title":"Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review.","authors":"Chen-Hua Liu, Yu-Ping Chang, Jia-Horng Kao","doi":"10.1080/14656566.2024.2396024","DOIUrl":"10.1080/14656566.2024.2396024","url":null,"abstract":"Introduction: Pharmacotherapy against hepatitis C virus (HCV) infection has tremendously improved since the advent of interferon (IFN)-free direct-acting antivirals (DAAs). Additionally, fixed-dose pangenotypic DAAs, which are safe, potent, easy for use, and can cover a wide spectrum of patients, have been recommended by professional guidelines for DAA-naïve and DAA-experienced patients with HCV.Areas covered: We review the pharmacokinetics, pharmacodynamics, and potential drug-drug interactions (DDIs) of fixed-dose pangenotypic DAA regimens, including glecaprevir/pibrentasvir (GLE/PIB), sofosbuvir/velpatasvir (SOF/VEL), and sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX). Additionally, we summarize the efficacy and safety of these regimens in clinical trials as well as real-world studies for treating different populations. Lastly, we discuss unmet medical needs in managing HCV in the era of fixed-dose pangenotypic DAAs.Expert opinion: Protease inhibitors (PIs), including GLE and VOX, are prone to have more frequent DDIs, compared to the non-structural (NS) 5A and 5B inhibitors. These regimens are generally well tolerated and can be applied to different populations, except for the contraindicated use of PI-containing DAA regimens in decompensated cirrhosis. Using the first-line GLE/PIB and SOF/VEL can eradicate HCV in more than 95% of DAA-naïve patients across different populations. The viral cure usually exceeds 95% when using the rescue SOF/VEL/VOX regimen for prior DAA failures.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of approved anti-obesity medications on osteoarthritis. 已获批准的抗肥胖药物对骨关节炎的影响。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-08-01 Epub Date: 2024-08-12 DOI: 10.1080/14656566.2024.2391524

Onur Baser, Katarzyna Rodchenko, Elizabeth Vivier, Isabel Baser, Yuanqing Lu, Munira Mohamed

{"title":"The impact of approved anti-obesity medications on osteoarthritis.","authors":"Onur Baser, Katarzyna Rodchenko, Elizabeth Vivier, Isabel Baser, Yuanqing Lu, Munira Mohamed","doi":"10.1080/14656566.2024.2391524","DOIUrl":"10.1080/14656566.2024.2391524","url":null,"abstract":"Background: Obesity has been established as a significant risk factor for osteoarthritis. Anti-obesity medications (AOMs) have demonstrated efficacy in weight management. However, potential impact on osteoarthritis risk remains uncertain.Methods: This retrospective cohort study used Kythera data from NOV2022 to JULY2024. Patients with obesity using AOMs were identified through diagnosis and prescription claims for tirzepatide, semaglutide, or liraglutide between 1NOV2023 and 31JAN2024, with a 6-month follow-up to assess OA risk. OA risk, analyzed using Cox regression and propensity score matching, controlled for comorbidities and sociodemographic factors.Results: There were 39,394 patients living with obesity using AOM (23,933 semaglutide 12,854 tirzepatide, 2,607 liraglutide) and 72,405 without AOM use. The adjusted osteoarthritis risk was 27% % lower in AOM users than in non-users (hazard ratio (HR) = 073, 95% CI (0.67-0.79), p < 0.01). Among AOMs, tirzepatide was associated with a significantly lower osteoarthritis (OA) risk compared to semaglutide (HR = 0.57, 95% CI: 0.50-0.65, p < 0.0001). Liraglutide was linked to a significantly higher OA risk vs tirzepatide (HR = 1.63, 95% CI: 1.23-2.15, p = 0.0007).Conclusions: AOM use was associated with a significantly lower risk of OA and may be an effective obesity management intervention.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141916490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0